Our findings highlight a critical role of the TRAF3/ECH1 axis in the oxidation of PUFAs, and targeting the axis represents a promising strategy to repress GBM growth and enhance the vulnerability of GBM to immunotherapies. The gene discussed is ECH1; the disease is glioblastoma.